Current point-of-care testing (POCT) glucometers are based on various test principles. Two major method groups dominate the market: glucose oxidase-based systems and glucose dehydrogenase-based systems using pyrroloquinoline quinone (GDH-PQQ) as a cofactor. The GDH-PQQ-based glucometers are replacing the older glucose oxidase-based systems because of their lower sensitivity for oxygen. On the other hand, the GDH-PQQ test method results in falsely elevated blood glucose levels in peritoneal dialysis patients receiving solutions containing icodextrin (e.g., Extraneal; Baxter, Brussels, Belgium). Icodextrin is metabolized in the systemic circulation into different glucose polymers, but mainly maltose, which interferes with the GDH-PQQ-based method. Clinicians should be aware of this analytical interference. The POCT glucometers based on the GDH-PQQ method should preferably not be used in this high-risk population and POCT glucose results inconsistent with clinical suspicion of hypoglycemic coma should be retested with another testing system.
WolfsonM., PirainoB., HamburgerR.J., MortonR.A randomized controlled trial to evaluate the efficacy and safety of icodextrin in peritoneal dialysis.Am J Kidney Dis2002; 40: 1055–65.
2.
WolfsonM., OgrincF., MujaisS.Review of clinical trial experience with icodextrin.Kidney Int Suppl2002; 81: S46–52.
3.
Garcia-LopezE., LindholmB., TranaeusA.Biocompatibility of new peritoneal dialysis solutions: clinical experience.Perit Dial Int2000; 20(Suppl 5): S48–56.
4.
MortierS., FaictD., SchalwijkC.G., LameireN.H., De VrieseA.S.Long-term exposure to new peritoneal dialysis solutions: effects on the peritoneal membrane.Kidney Int2004; 66: 1257–65.
5.
PosthumaN., ter WeeP.M., DonkerA.J., OeP.L., PeersE.M., VerbrughH.A.Assessment of the effectiveness, safety, and biocompatibility of icodextrin in automated peritoneal dialysis. The Dextrin in APD in Amsterdam (DIANA) Group.Perit Dial Int2000; 20(Suppl 2): S106–13.
6.
MistryC.D., GokalR.The use of glucose polymer (icodextrin) in peritoneal dialysis: an overview.Perit Dial Int1994; 14(Suppl 3): S158–61.
7.
JelokaT.K., ErsoyF.F., YavuzM., SahuK.M., CamsariT., UtasC.What is the optimal dwell time for maximizing ultrafiltration with icodextrin exchange in automated peritoneal dialysis patients?Perit Dial Int2006; 26: 336–40.
8.
KredietR., MujaisS.Use of icodextrin in high transport ultrafiltration failure.Kidney Int Suppl2002; 81: S53–61.
9.
KredietR.T., van WestrhenenR., ZweersM.M., StruijkD.G.Clinical advantages of new peritoneal dialysis solutions.Nephrol Dial Transplant2002; 17(Suppl 3): S16–18.
10.
WoodrowG., StablesG., OldroydB., GibsonJ., TurneyJ.H., BrownjohnA.M.Comparison of icodextrin and glucose solutions for the daytime dwell in automated peritoneal dialysis.Nephrol Dial Transplant1999; 14: 1530–5.
11.
RileyS.G., ChessJ., DonovanK.L., WilliamsJ.D.Spurious hyperglycaemia and icodextrin in peritoneal dialysis fluid.BMJ2003; 327: 608–9.
12.
MistryC.D., GokalR., PeersE.A randomized multicenter clinical trial comparing isomolar icodextrin with hyperosmolar glucose solutions in CAPD. MIDAS Study Group. Multicenter Investigation of Icodextrin in Ambulatory Peritoneal Dialysis.Kidney Int1994; 46: 496–503.
13.
BabazonoT., NakamotoH., KasaiK., KuriyamaS., SugimotoT., NakayamaM.Effects of icodextrin on glycemic and lipid profiles in diabetic patients undergoing peritoneal dialysis.Am J Nephrol2007; 27: 409–15.
14.
BredieS.J., BoschF.H., DemackerP.N., StalenhoefA.F., van LeusenR.Effects of peritoneal dialysis with an overnight icodextrin dwell on parameters of glucose and lipid metabolism.Perit Dial Int2001; 21: 275–81.
15.
DaviesS.J., WoodrowG., DonovanK., PlumJ., WilliamsP., JohanssonA.C.Icodextrin improves the fluid status of peritoneal dialysis patients: results of a double-blind randomized controlled trial.J Am Soc Nephrol2003; 14: 2338–44.
16.
CanbakanM., SahinG.M.Icodextrin and insulin resistance in continuous ambulatory peritoneal dialysis patients.Ren Fail2007; 29: 289–93.
17.
GürsuE.M., OzdemirA., YalinbasB., GürsuR.U., CanbakanM., GüvenB.The effect of icodextrin and glucose-containing solutions on insulin resistance in CAPD patients.Clin Nephrol2006; 66: 263–8.
18.
JanssenW., HarffG., CaersM., SchellekensA.Positive interference of icodextrin metabolites in some enzymatic glucose methods [Letter].Clin Chem1998; 44: 2379–80.
19.
MoberlyJ.B., MujaisS., GehrT., HamburgerR., SpragueS., KucharskiA.Pharmacokinetics of icodextrin in peritoneal dialysis patients.Kidney Int Suppl2002; 81: S23–33.
20.
WangR., SkoufosL., MartisL.Glucose monitoring for diabetic patients using icodextrin.Perit Dial Int2004; 24: 296–7.
21.
DaviesD.S.Kinetics of icodextrin.Perit Dial Int1994; 14(Suppl 2): S45–50.
22.
Garcia-LopezE., AnderstamB., HeimbürgerO., AmiciG., WerynskiA., LindholmB.Determination of high and low molecular weight molecules of icodextrin in plasma and dialysate, using gel filtration chromatography, in peritoneal dialysis patients.Perit Dial Int2005; 25: 181–91.
23.
PlumJ., GentileS., VergerC., BrunkhorstR., BahnerU., FallerB.Efficacy and safety of a 7.5% icodextrin peritoneal dialysis solution in patients treated with automated peritoneal dialysis.Am J Kidney Dis2002; 39: 862–71.
24.
D'CostaE.J., HigginsI.J., TurnerA.P.F.Quinoprotein glucose dehydrogenase and its application in an amperometric glucose sensor.Biosensors1986; 2: 71–87.
25.
DuineJ.A.Quinoproteins: enzymes containing the quinonoid cofactor pyrroloquinoline quinone, topaquinone or tryptophan-tryptophan quinone.Eur J Biochem1991; 200: 271–84.
26.
SchleisT.G.Interference of maltose, icodextrin, galactose, or xylose with some blood glucose monitoring systems.Pharmacotherapy2007; 27: 1313–21.
27.
GainesA.R., PierceL.R., BernhardtP.A.Fatal iatrogenic hypoglycemia: falsely elevated blood glucose readings with a point-of-care meter due to a maltose-containing intravenous immune globulin product. Available at: http://www.fda.gov/cber/safety/glucfalse.htm
28.
WensR., TaminneM., DevriendtJ., CollartF., BroedersN., MestrezF.A previously undescribed side effect of icodextrin: overestimation of glycemia by glucose analyzer.Perit Dial Int1998; 18: 603–9.
29.
WangX.G., BrittonK.L., StillmanT.J., RiceD.W., EngelP.C.Conversion of a glutamate dehydrogenase into methionine/norleucine dehydrogenase by site-directed mutagenesis.Eur J Biochem2001; 268: 5791–9.
30.
HoenesJ., UnkrigV.Method for the colorimetric determination of an analyte with PQQ-dependent dehydrogenase. US Patent 5484708.
31.
DuineJ.A., JongejanJ.A.Quinoproteins, enzymes with pyrrolo-quinoline quinone as cofactor.Annu Rev Biochem1989; 58: 403–26.
32.
OlsthoornA.J., DuineJ.A.Production, characterization, and reconstitution of recombinant quinoprotein glucose dehydrogenase (soluble type; EC1.1.99.17) apoenzyme of Acinetobacter calcoaceticus.Arch Biochem Biophys1996; 336: 42–8.
33.
IgarashiS., OhteraT., YoshidaH., WitartoA.B., SodeK.Construction and characterization of mutant water-soluble PDD glucose dehydrogenase with altered K(m) values—site-directed mutagenesis studies on the putative active site.Biochem Biophys Res Commun1999; 264: 820–4.
34.
DokterP., FrankJ., DuineJ.A.Purification and characterization of quinoprotein glucose dehydrogenase from Acinetobacter calcoaceticus L.M.D.79.41.Biochem J1986; 239: 163–8.
FloréK., DelangheJ.R.Icodextrin: a major problem for glucose dehydrogenase-based glucose point of care testing systems.Acta Clin Belg2006; 61: 351–4.
37.
de WaartD.R., ZweersM.M., StruijkD.G., KredietR.T.Icodextrin degradation products in spent dialysate of CAPD patients and the rat, and its relation with dialysate osmolality.Perit Dial Int2001; 21: 269–74.
38.
SlimS., GriffithsM.J., GamaR.Icodextrin still a cause for concern with blood glucose monitoring in continuous ambulatory peritoneal dialysis patients with diabetes [Letter].Ann Clin Biochem2007; 44: 196–7.
39.
GrzegorzewskaA.E., Antczak-JedrzejczakD., MariakI.Polyglucose dialysis solution influences serum activity of amylase and of lipase differently.Adv Perit Dial2000; 16: 113–18.
40.
SchoenickeG., GrabenseeB., PlumJ.Dialysis with icodextrin interferes with measurement of serum alpha-amylase activity.Nephrol Dial Transplant2002; 17: 1988–92.
41.
AnderstamB., Garcia-LopezE., HeimbürgerO., LindholmB.Determination of alpha-amylase activity in serum and dialysate from patients using icodextrin-based peritoneal dialysis fluid.Perit Dial Int2003; 23: 146–50.
42.
WangR., LeeschV., TurnerP., MoberlyJ.B., MartisL.Kinetic analysis of icodextrin interference with serum amylase assays.Adv Perit Dial2002; 18: 96–9.
43.
MistryC.D., GokalR.Single daily overnight (12-h dwell) use of 7.5% glucose polymer (Mw 18700; Mn 7300) +0.35% glucose solution: a 3-month study.Nephrol Dial Transplant1993; 8: 443–7.
44.
Garcia-LopezE., WerynskiA., HeimbürgerO., FilhoJ.C., LindholmB., AnderstamB.Rate of synthetic oligosaccharide degradation as a novel measure of amylase activity in peritoneal dialysis patients.Perit Dial Int2008; 28: 296–304.
45.
FDA.Important Safety Information on Interference with Blood Glucose Measurement Following Use of Parenteral Maltose/Parenteral Galactose/Oral Xylose-Containing Products. 9 November 2005. Available at: www.fda.gov/cber/safety/maltose110405.htm
Roche Diagnostics Corporation.Safety Alert [ACCU-CHEK Blood Glucose Monitoring Systems—Reminder of Potential for Falsely Elevated Blood Glucose Readings due to Drug Interferences], September 7, 2006. Available at: http://www.accuchek.com/en_US/pdf/06_205POC_MaltoseSafetyAlert.pdf
49.
MehmetS., QuanG., ThomasS., GoldsmithD.Important causes of hypoglycaemia in patients with diabetes on peritoneal dialysis.Diabet Med2001; 18: 679–82.
50.
DisseE., ThivoletC.Hypoglycaemic coma in a diabetic patient on peritoneal dialysis due to interference of icodextrin metabolites with capillary blood glucose measurements [Letter].Diabetes Care2004; 27: 2279.
51.
HoftmanN.Interference between Extraneal peritoneal dialysis and the Accu-Chek blood glucose monitor [Letter].Anesthesiology2005; 102: 871.
52.
LauC., BorgmannS., MaciejewskaM., NgounouB., GründlerP., SchuhmannW.Improved specificity of reagentless amperometric PQQ-sGDH glucose biosensors by using indirectly heated electrodes.Biosens Bioelectron2007; 22: 3014–20.
